Annovis Bio, touting new Alzheimer's data, rips into Biogen's Aduhelm: It is not 'remotely as good …

Eyes, money and renewed interest have poured into the Alzheimer’s space in the past seven weeks following the FDA’s controversial green light for Biogen’s drug Aduhelm. But Annovis Bio thinks the specific interest in its company is due to data on its own AD treatment hopeful, which improves cognition by 30% in 25 days.  The biotech said Wednesday that its oral drug, being tested in both Alzheimer’s and Parkinson’s disease patients, normalized biomarkers in phase 2a studies. The level of neurotoxic proteins were normalized, meaning they came down, axonal health was restored, inflammation was lowered and neurofilament light was also lowered, said CEO Maria Maccecchini, Ph.D., in an interview with Fierce Biotech.  RELATED: Biogen’s Aduhelm win opened up market frenzy for Alzheimer’s-focused companies The data, presented Wednesday night at the 2021 Alzheimer’s Association International Conference in Denver, adds to the positive results that the biotech released in May. Improving cognition At that time, Annovis said the drug, dubbed ANVS401, improved cognition by 4.4 points for a statistically significant improvement of 30% after 25 days, based on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 11.  In early June, Annovis also said AD and PD patients in the phase 2a study showed a statistically significant increase of 23% to…
Read More